Hotels are doing the heavy lifting, offices are not


Covivio does not trade like a pure office landlord, and that is the first thing to keep in view. The company sits in European commercial real estate, but the portfolio is split across offices, German residential, and hotels, which means the stock lives or dies on a mix of rent resilience, asset rotation, and whether hospitality can keep doing the work that offices have stopped doing. That mix has mattered more this year because the listed property tape has been pulled in two directions at once. Long rates remain awkward. Hotel demand, especially in Southern Europe, has been better than the office backdrop deserves.
Covivio’s own half-year numbers tell you why the market has been willing to listen. In its July 20 release, the company said first-half 2026 like-for-like revenue rose 2.1%, including 3.2% in variable revenues, and recurring earnings per share increased 7%. It also confirmed full-year guidance of around 4% growth in recurring net result per share. That is not a heroic growth profile. It is, however, the kind of steady operating print that can support a rerating when the sector is still being priced through a rate lens rather than a growth lens. Goldman Sachs leaned into that on September 7, upgrading Covivio to Buy from Neutral with a EUR 60 target, pointing to the company’s growing Southern European hotel exposure.
The stock itself has not been sitting still either. It closed around EUR 47.68 on September 10 and then traded near EUR 47.78 to EUR 48.54 in the following sessions, which is a useful reminder that the market was already digesting the hotel story, the rate backdrop, and the Goldman call before the filings hit. That matters because insider buying in a vacuum is one thing. Insider buying after a sector has already started to reprice is another. You are not looking for a miracle. You are looking for whether the people with board access are still willing to add at a level where the market has already done some of the work.
On September 11, Giovanni Giallombardo bought twice, with filings valued at about EUR 48,350 and EUR 47,641, euro-normalised filing values from the AMF disclosures. DFR Investment SARL, linked to board members, also bought twice that day, with holdings worth roughly EUR 339,986 and EUR 338,146. Four buy filings in one session is not noise. It is a cluster, and it came from two distinct insiders. InsiderTrades data marks the display score at 4.4, which is a modest read rather than a siren, but the composition matters more than the number here: an operating director, plus an affiliated vehicle tied to board members, both adding on the same date.
The size is the other obvious point. Each filing is tiny beside Covivio’s EUR 5.56bn market value. Giallombardo’s two purchases are small enough to fit inside a rounding error on the company’s equity base, and even the DFR Investment SARL buys sit well below 0.01% of market cap. That does not make them meaningless. It does make them easier to interpret as positioning, not as a balance-sheet statement. If you want a grand theory, you will not get one from these numbers. If you want a board-level read on whether the stock still looks acceptable at the current price, this is the sort of paper trail you actually get.
The cluster also fits the recent declaration pattern. InsiderTrades data shows 12 recent declarations, with six of the recent entries in the dossier coming from DFR Investment SARL and Giallombardo across September 8, 9, and 11. That is the part that keeps this from looking like a one-off. The market often overreacts to a single buy from a director who has not been active in months. Here, the activity is repeated, and it is repeated by affiliated parties. That is a different read.
Covivio’s hotel exposure is the real operating lever in this story. The company has actively increased that exposure, especially in Southern Europe, where demand has been resilient enough to support the revenue line. The half-year release said the first six months of 2026 were driven by active asset management, and the company highlighted the centrality of its portfolio after reinforcing hotel exposure. That is not a cosmetic shift. It is a deliberate tilt toward a segment that has been able to grow while parts of the office market remain stuck in slow motion.
The broader hotel backdrop helps explain why the market has been willing to pay attention. European hotel performance rose 2.2% through May 2026, led by Italy and Spain. That is the kind of regional detail that matters for Covivio because the company is not just buying generic hospitality exposure. It is leaning into a geography where demand has been better than the continental average. When a landlord with office baggage can point to hotel growth in Italy and Spain, the market tends to listen more closely than it would to another office landlord promising patience.
This is also why the peer set matters. Unibail-Rodamco-Westfield and Klepierre sit in retail, which has its own rhythm and its own problems. Gecina is more concentrated in French offices, which means it is closer to the part of the market that still has to prove it can reprice through higher-for-longer rates. Covivio sits between those worlds. It has office exposure, but it also has German residential and a hotel book that has become more important to the story. That mix gives it a different sensitivity to the sector than a pure office name, and a different earnings path than a mall landlord.
The recent hotel ownership consolidation with AccorInvest, completed around September 10, only sharpens that point. Covivio is not just talking about hotels as a theme. It has been consolidating the exposure. That is the sort of strategic move that can change how the market values the portfolio, because it shifts the earnings mix toward the segment with the better near-term demand backdrop. You do not need to overstate it. You just need to notice that the company has been moving in the direction the market has preferred.

The macro backdrop is still doing the heavy lifting on valuation. The ECB raised its key deposit rate by 25 basis points to 2.50% in September 2026, with staff projections showing euro area GDP growth of 0.9% for 2026 and HICP inflation at 3.0%. That is not a friendly setting for property yield compression. Higher long-term yields keep a lid on how aggressively listed real estate can rerate, even when the operating numbers are improving. The market can reward income and asset quality, but it is not handing out free multiples just because one segment is working better than another.
That is why Covivio’s hotel tilt matters more than a generic “real estate is cheap” argument. In a higher-rate world, investors want assets with rental momentum and visible cash generation. Hotels can offer that, especially when demand is still firm in the right geographies. Offices can do the opposite if leasing weakens or cap rates stay sticky. Covivio’s diversified model gives it some insulation, but it also means the stock is constantly being judged on whether the better parts of the portfolio can offset the drag from the weaker ones.
The market has already started to reflect that tension. The stock’s recent trading range around the high EUR 47s and low EUR 48s sits below Goldman’s EUR 60 target, but a target is not a thesis by itself. What matters is whether the company can keep turning the hotel exposure into earnings while the rate backdrop remains restrictive. The half-year guidance suggests management thinks it can. The insider cluster suggests at least some board-level holders are willing to buy that argument at current levels.
InsiderTrades data gives Covivio a display score of 4.4, and the rationale is straightforward enough. The buys were filed by an operating director, they came as part of an insider cluster, and the amounts were negligible relative to market value. That is enough to keep the signal in the frame, but not enough to turn it into a grand thesis. The score is a screen, not a verdict. It helps you separate a routine filing from one that deserves a second look, and this one deserves that look because the buying was repeated, affiliated, and close in time to the company’s strategic and operating updates.
The historical cohort data is the more useful context. For director-level buys at large-cap names, the sample size is 5,415, with a 90-day win rate of 55.7%, an average 90-day return of 3.32%, and an average 365-day return of 90.35%. That is historical cohort data for a role-and-size bucket, not a forecast for Covivio and not a promise that this trade will behave the same way. It tells you that director buys in large caps have, on average, been associated with modest short-term follow-through and much stronger long-run dispersion, but it does not tell you which path this stock will take from here.
That caveat matters because Covivio is not a clean one-factor trade. The company has a real operating story, a real rate sensitivity, and a real sector rotation angle. A director buy can line up with all of that, or it can simply reflect a view that the stock is acceptable at a given price. You do not get to infer more than the filing supports. What you can say is that the buying arrived in a name where the business mix has improved, the hotel exposure has become more central, and the market has already started to reward that shift.
The most interesting thing about Covivio is not that it owns real estate. Plenty of companies do. It is that the company has been changing the quality of the earnings mix while the sector still trades under the shadow of rates. That combination is why the stock has a case for further rerating if the hotel contribution keeps holding up and the office drag stays contained. The half-year numbers show the operating engine is still working. The Goldman upgrade shows at least one large house thinks the market has not fully caught up. The insider cluster adds a board-level willingness to buy into that same setup.
You should still keep the risks in view. Higher rates can stay higher for longer. Office markets can stay weak longer than the market wants to admit. A hotel-heavy tilt helps only if demand stays resilient in the right regions, and Covivio’s own mix means the company is never fully insulated from the parts of the property market that are still under pressure. The filings do not erase that. They do not need to. They simply tell you that, at least on September 11, two connected insiders were willing to add exposure while the stock was trading in the high EUR 47s.
That is the practical point. Covivio is a listed property name with a better hotel story than most of its office-heavy peers, a recent analyst upgrade, and a cluster of board-linked buying that arrived after the stock had already moved into the high EUR 47s. The next thing to watch is whether the company can keep translating that hotel exposure into recurring earnings when the next set of results lands, because that is where the rerating either earns its keep or stalls out.
The market will not pay forever for a good story if the numbers stop cooperating. Covivio’s next update has to show that the hotel contribution is still doing the work, that the office book is not dragging harder than expected, and that the company can keep defending the around 4% recurring net result per share guidance it set in July. If that happens, the September buying cluster will look like a sensible board-level add at a name with improving fundamentals. If it does not, the filings will shrink back to what they always are, a useful clue, not a substitute for earnings.
For now, the setup is straightforward. A higher-rate European property market is still sorting winners from laggards. Covivio has been leaning into hotels, especially in Southern Europe. The stock has already responded some, but not enough to make the Goldman target look absurd. And on September 11, Giovanni Giallombardo and DFR Investment SARL both bought again. That is the fact pattern to carry into the next release, not a promise, just the next thing the market will have to price.
Dig deeper: COVIVIO's full insider filing history.
This is not investment advice.
GSK executives bought 14 shares each at £18.0296 on September 9. Read the cluster against pharma peers, Q2 guidance, and...
Interparfums drew fresh insider buying in September as luxury stays uneven, fragrance holds up, and the stock trades nea...
Rolls-Royce directors bought again on 10 September as aerospace and defence stays firm, after July’s raised guidance and...
GSK’s 10-person buy cluster is tiny in cash terms, but it arrives as pharma trades through trial risk, rate pressure and...
Renault’s latest insider selling lands as European autos wrestle with margin pressure, ECB tightening and a six-name sel...
Viaplay’s latest SEK 1.33 buy lands after a 10-insider cluster, a Q2 margin lift, and a Dutch sale that sharpens the Nor...